

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT				
NATURE OF CONVEYANCE:	ASSIGNMENT				
CONVEYING PARTY DATA					
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Medivir AB</td> <td>06/28/2011</td> </tr> </tbody> </table>		Name	Execution Date	Medivir AB	06/28/2011
Name	Execution Date				
Medivir AB	06/28/2011				
RECEIVING PARTY DATA					
Name:	Meda Pharma Sarl				
Street Address:	46A Avenue John Fitzgerald Kennedy				
City:	Grand-Duchy of Luxembourg				
State/Country:	LUXEMBOURG				
Postal Code:	L-1855				
PROPERTY NUMBERS Total: 1					
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>10334487</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	10334487
Property Type	Number				
Application Number:	10334487				
CORRESPONDENCE DATA					
Fax Number:	(202)371-2540				
Phone:	202-371-2600				
Email:	mkoper@skgf.com, eheenan@skgf.com, pjackman@skgf.com				
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>					
Correspondent Name:	Sterne, Kessler, Goldstein, & Fox PLLC				
Address Line 1:	1100 New York Avenue, PLLC				
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20005				
NAME OF SUBMITTER:	/ Peter A. Jackman, #45,986 /				
<p>Total Attachments: 4 source=2286_309_1_assignment#page1.tif source=2286_309_1_assignment#page2.tif source=2286_309_1_assignment#page3.tif source=2286_309_1_assignment#page4.tif</p>					

OP \$40.00 10334487

PATENT ASSIGNMENT

THIS AGREEMENT is dated

28 JUNE

2011

PARTIES

- (1) **MEDIVIR AB**, a company registered in Sweden and having its principal place of business Lunastigen 7, 141 22 Huddinge, Sweden (the "Assignor").
- (2) **MEDA PHARMA SARL** a company incorporated in Luxembourg, with a principal place of business at 46A Avenue John Fitzgerald Kennedy, L-1855, Luxembourg, Grand-Duchy of Luxembourg (the "Assignee").

BACKGROUND

- (A) The Assignor is the proprietor of the patents granted or the subject of applications for grant in the countries listed in the Schedule 3H(i) ("Assigned Patents").
- (B) By a buy out agreement between the parties entered into on the date of this agreement (the "Buy Out Agreement"), the Assignor has agreed to assign all its rights in and to the Assigned Patents to the Assignee on the terms set out below.

AGREED TERMS

1. Assignment

In consideration for entering into the Buy Out Agreement and the payment thereunder, the Assignor hereby sells and assigns to the Assignee, all right and title and interest in and to the Assigned Patents (including the right of suit for any instances of infringement of the Assigned Patents prior to the date of this Agreement).

2. Further assurance

Subject to any provisions of the Buy Out Agreement, the Assignor shall cooperate with the Assignee in executing and delivering all notices, agreements, applications, submissions, reports and other instruments and documents that are necessary, proper or advisable under applicable laws, or in obtaining any consents, to consummate and make effective the assignment contemplated by this agreement and to allow Assignee the full benefit of the Assigned Patents and the rights hereby assigned.

3. Entire Agreement

This agreement together with the Buy Out Agreement, constitutes the entire understanding and agreement of the parties with respect to the subject matter hereof and cancels and supersedes all prior agreements, whether verbal or written, between the parties with respect to the subject matter hereof. Each party acknowledges that, in entering into this agreement, it has not relied on, and, to the extent permitted by law, shall have no right or remedy in respect of, any statement, representation, assurance or

EME_ACTIVE-553346006.1


15/06/11

warranty (whether made negligently or innocently) other than as expressly set out in this agreement. No modification of any provision of this agreement shall be effective unless made in writing and signed by a duly authorized officer of both of the parties.

4. Governing law and jurisdiction

This agreement shall be governed by and construed in accordance with Swedish law and Potential disputes or controversies arising out of or relating to this agreement shall be subject to and be resolved in accordance with Clause 15.10 of the Buy Out Agreement.


This agreement has been entered into on the date stated at the beginning of it.



Schedule 3H(i) Assigned Patents

		Priority Date From Pat:	Country	Title	Status and Expiration
1.	US 7,223,387*	18.10.2009/ 29.05.2007	US	Antiviral formulations comprising propylene glycol and an isopropyl alcanoic acid ester	Granted Expires on 28.02.2021
2.	CA 2,351,463*	12.11.1999/ 13.10.2009	Canada	Ditto	Granted Expires on 12.11.2019
3.	MX 244,237*	12.11.1999/ 20.03.2007	Mexico	Ditto	Granted Expires on 12.11.2019
4.	US 12/403665	13.03.2009	US	Antiviral formulation	Pending
5.	CA 2,717,440	17.03.2009	Canada	Ditto	Pending
6.	MX/a/2010/01008 9	17.03.2009	Mexico	Ditto	Pending


Signed on behalf of MEDIVIR AB



Director^{CEO}

IAIN MORRISON
Authorized signatory

Signed on behalf of MEDA
PHARMA SARL



Director

INGO HENNING
MANAGING DIRECTOR

